Loading...
| This week's Fierce Biotech is brought to you by Hanson Wade. |
| We are excited to invite you to the first-ever industry-led virtual forum solely dedicated to fully harnessing the therapeutic value of ubiquitin E3 ligases - the inaugural Ligase Targeting Drug Development Summit (May 25-27, 2021). Arvinas, Kymera, Cullgen, PhoreMost & Plexium are just a snapshot of the pioneering organizations that are coming together at this year’s summit to deep-dive into the fundamental challenges of harnessing E3’s for therapeutic application in protein degradation and beyond. What can you expect to learn at the summit? Enhance Specificity & Expression - through expression data and tissue-specific ubiquitin ligases, discover how to access broader applications for targeted protein degradation Explore E3 Structure & Function - deep dive into fundamental structural components of ubiquitin ligases and protein-substrate complexes to advance E3 druggability Advance Selection & Validation - discuss the untouched landscape of hard-to-drug ubiquitin ligases, and uncover what makes them tough to target and difficult to select Optimize Chemical Tools - expand chemical biology tools to therapeutically leverage ubiquitin ligases for effective protein modulation or degradation strategies Improve Ligand Development - reveal effective strategies for selection and optimization of chemical binders to advance E3’s into effective therapeutic strategiesFind out more in the complete event guide here! Join 100+ leading biopharmaceutical companies this year from the likes of Frontier Medicines, Celgene, Nurix, BMS, Merck, Vividion Therapeutics & many more, as we join forces to bridge the gap between the functional knowledge and true translational value of ubiquitin ligases and their associated ligands. The Ligase Targeting Drug Development Summit Team |
| Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Questex, LLC |
Loading...
Loading...
